

May 29, 2017

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma Announces Voluntary Adoption of International Financial Reporting Standards (IFRS)

Sumitomo Dainippon Pharma Co., Ltd. announced today that, in its meeting held on May 29, 2017, the Board of Directors decided to adopt voluntarily the International Financial Reporting Standards (IFRS) for consolidated financial statements from the end of the fiscal year ending March 31, 2018, in place of Japanese Generally Accepted Accounting Principles (J-GAAP) currently followed. The aims include improving the international comparability of the Group's financial statements in the capital markets and improving the business management within the Group by standardizing accounting treatment.

Planned disclosure schedule for IFRS voluntary adoption

Fiscal Year		Disclosure Item	Accounting Standard
Ending March 31, 2018	1 st quarter through 3 rd quarter	Quarterly summary of consolidated financial results	J-GAAP
		Quarterly securities report	
	End of fiscal year	Summary of consolidated financial results	IFRS
		Consolidated financial statements	
		Annual securities report	

(Reference)

Consolidated forecasts for the Fiscal Year Ending March 31, 2018 under IFRS (rough estimate)
(Billions of yen)

	J-GAAP (A)	IFRS (estimate) (B)	Difference (B-A)
Net Sales	450.0	450.0	0.0
Operating Income	55.0	54.0	(1.0)
Net Income attributable to owners of the parent	36.0	34.0	(2.0)

Contact:

Public Relations/Investor Relations

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)